<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310296</url>
  </required_header>
  <id_info>
    <org_study_id>USWM-LX1-1003/ 02749MZ</org_study_id>
    <nct_id>NCT01310296</nct_id>
  </id_info>
  <brief_title>Lofexidine ADME &amp; Mass Balance in Volunteers</brief_title>
  <official_title>A Single-Center, Open-Label, Two-Period, Two-Treatment, Randomized Sequence Study to Determine the Mass Balance and Absolute Bioavailability of a Single Oral Dose of 14C-Labeled Lofexidine Compared to a Single Intravenous Dose of Lofexidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US WorldMeds LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>US WorldMeds LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the mass balance and absolute bioavailability of a
      single oral dose of 14C-labeled lofexidine compared to a single intravenous dose of
      lofexidine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance</measure>
    <time_frame>plasma, urine, and fecal samples up to 216 hours post dose</time_frame>
    <description>To determine the mass balance recovery of orally administered lofexidine hydrochloride</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Bioavailability &amp; Tolerability</measure>
    <time_frame>plasma samples over 72 and 144 hrs post-dose for IV and oral doses, respectively</time_frame>
    <description>To determine the absolute bioavailability of a single oral dose of lofexidine compared to a single intravenous dose of lofexidine
To determine the tolerability of lofexidine oral solution and intravenous lofexidine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product</condition>
  <arm_group>
    <arm_group_label>Radiolabeled Lofexidine Oral Solution</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive a radiolabeled lofexidine oral solution followed by safety evaluations, and plasma, urine and fecal sampling for up to 216 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lofexidine Intravenous Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 200 mcg of lofexidine in an intravenous solution infusion over 200 minutes followed by 72 hours of safety evaluation and plasma sampling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine hydrochloride</intervention_name>
    <description>Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine</description>
    <arm_group_label>Radiolabeled Lofexidine Oral Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine hydrochloride</intervention_name>
    <description>Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min</description>
    <arm_group_label>Lofexidine Intravenous Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be a male or non-pregnant, non-breastfeeding female.

          -  Subject must be between 18 and 50 years of age (inclusive).

          -  Subject's Body Mass Index (BMI) must be between 18 and 30 kg/m2 (inclusive), and
             subject must weigh a minimum of 50 kg (110 lbs).

          -  Female subjects must agree to use one of the following forms of birth control from
             screening until 14 days after completion of the study:

          -  Vasectomized partner (at least 6 months prior to dosing)

          -  Post-menopausal (at least 2 years prior to dosing)

          -  Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) at
             least 6 months prior to dosing

          -  Double barrier (diaphragm with spermicide; condoms with spermicide)

          -  IUD (intra-uterine device)

          -  Abstinence (must agree to use a double barrier method if they become sexually active
             during the study)

          -  Implanted or intrauterine hormonal contraceptives in use for at least 6 consecutive
             months prior to study dosing and throughout the study duration

          -  Oral, patch, and injected contraceptives or vaginal hormonal device (i.e. NuvaRing®)
             in use for at least 3 consecutive months prior to study dosing and throughout the
             study duration.

          -  Subject must voluntarily consent to participate in this study and provide their
             written informed consent prior to start of any study- specific procedures.

          -  Subject is willing and able to remain in the study unit for the entire duration of
             each confinement period.

          -  Subject's vital signs must be within the following ranges to be included: Vital signs
             measured sitting after 3 minutes rest; heart rate: 50-90 bpm; systolic BP: 100-140
             mmHg; diastolic BP: 50-90 mmHg, and oral temperature within the normal range of
             35.6-37.7° C. Out-of-range vital signs may be repeated once. Predose vital signs will
             be assessed by the Principal Investigator or designee (e.g., a medically qualified
             sub-investigator) prior to study drug administration. The Principal Investigator or
             designee will verify the eligibility of each subject with out-of-range vital signs and
             document approval prior to dosing.

          -  For the study period in which the subject is assigned to receive Treatment A
             (lofexidine oral solution containing 14C-lofexidine), subject must be:

          -  Willing to eat entire meals and snacks provided during confinement at the research
             facility; and understand that the diet will include foods with high fiber content and
             possibly prune juice.

          -  Willing to remain in the clinical research center for a minimum of 7 consecutive days
             during pre-dose, dose, and post-dose evaluation periods. Subjects must be willing to
             stay for an additional 24 to 48 hours if necessary.

          -  Willing to collect all urine and fecal samples for the duration of the study period as
             required.

        Exclusion Criteria:

          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,
             neurologic, oncologic, or psychiatric disease or any other condition that, in the
             opinion of the Investigator, would jeopardize the safety of the subject or the
             validity of the study results.

          -  Has a clinically significant abnormal finding on the physical exam, medical history,
             ECG, or clinical laboratory results at screening.

          -  History of any syncopal episode or seizures.

          -  Presence of acute disease state (eg, nausea, vomiting, fever, diarrhea) within 7 days
             prior to scheduled dose administration.

          -  History or presence of allergic or adverse response to lofexidine or related drugs.

          -  Has been on a significantly abnormal diet during the 4 weeks preceding the first dose
             of study medication.

          -  Has donated blood or plasma within 30 days prior to the first dose of study
             medication.

          -  Has participated in a radiolabeled clinical trial within the last 12 months prior to
             the first dose of study medication.

          -  Has participated in another clinical trial (randomized subjects only) within 30 days
             prior to the first dose of study medication.

          -  Has used any over-the-counter (OTC) medication, including nutritional supplements,
             within 7 days prior to the first dose of study medication.

          -  Has used any prescription medication, except hormonal contraceptive or hormonal
             replacement therapy, within 14 days prior to the first dose of study medication.

          -  Subjects that have discontinued the use of implanted, intrauterine, or injected
             hormonal contraceptives must not have used any for 6 months prior to study start.

          -  Subjects that have discontinued the use of oral, patch, or vaginal hormonal
             contraceptives must not have used any for 1 month prior to study start.

          -  Has been treated with any known drugs that are moderate or strong inhibitors/inducers
             of CYP enzymes such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc.,
             within 30 days prior to the first dose of study medication and that in the
             Investigator's judgment may impact subject safety or the validity of the study
             results.

          -  Has smoked or used tobacco products within 60 days prior to the first dose of study
             medication.

          -  Has any prior history of substance abuse or treatment (including alcohol) within the
             past 2 years.

          -  Is a female with a positive pregnancy test result.

          -  Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,
             benzodiazepines, cocaine, cannabinoids, opiates).

          -  Has had a positive test for, or has been treated for hepatitis B, hepatitis C, or
             Human Immunodeficiency Virus (HIV).

          -  Has orthostatic hypotension at screening defined as a drop in systolic blood pressure
             ≥ 20 mmHg or a fall in diastolic blood pressure ≥ 10 mmHg following a 2 minute stand.
             Out-of-range vital signs may be repeated once. Predose vital signs will be assessed by
             the Principal Investigator or designee (e.g., a medically qualified sub-investigator)
             prior to study drug administration. The Principal Investigator or designee will verify
             the eligibility of each subject with out-of-range vital signs and document approval
             prior to dosing.

          -  Subjects with a QTcB greater than 450 msec (males) or greater than 470 msec (females),
             at screening obtained after 5 minutes rest in a supine position using the ECG machine
             algorithm.

          -  Has irregular bowel habits. (&quot;Irregular&quot; being defined for the purpose of this study
             as NOT having a bowel movement at least every 2 days.)

          -  Has been exposed to radiation, including dental or medical imaging such as x ray or
             tomography, in the 6 months prior to dose administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Longstreth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US WorldMeds</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles W Gorodetzky, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US WorldMeds</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Leibowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2011</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Normal Healthy Volunteers</keyword>
  <keyword>Mass Balance</keyword>
  <keyword>ADME</keyword>
  <keyword>Absolute Bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Lofexidine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

